This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

RECEIVED

APR 1 9 2002

COMMONWEALTH OF AUSTRALIA

TECH CENTER 1600/2900



Application 696764 (73941/94). In the pape of:

-and-

IN THE MATTER OF: Opposition The trans by Decearch under 1600/2900 Ludwig Institute for Cancer Research, under Section 59 of the Patents Act.

STATUTORY DECLARATION

- I, Susan Power of Cell & Molecular Technologies, Inc., Phillipsburg, New Jersey, United States of America, declare as follows:
 - At the request of the Patent Attorneys representing Human Genome Sciences 1. ("HGS") in connection with the Ludwig Institute for Cancer Research Opposition to the issuance of HGS Australian Patent Application 696764, in the name of HGS, entitled: "Vascular Endothelial Growth Factor-2" ("the HGS patent specification"), I performed certain experiments as described in a Statutory Declaration executed December 13, 2000 ("Power Declaration I"). The Patent Attorneys representing HGS have now requested that I provide additional information regarding those experiments and carry out additional experiments.
 - In particular, I have been asked to clarify the construction of the expression 2. vectors described in Power Declaration I used to determine whether the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence would result in the expression and secretion of the protein from eukaryotic cells.
 - 3. The Patent Attorneys representing HGS have requested that I perform additional experiments to determine whether the VEGF-2 coding sequence contained in ATCC Deposit No. 75698 fused in frame with a heterologous signal sequence would result in the expression and secretion of the protein

from eukaryotic cells. Further, the Patent Attorneys representing HGS have requested that I construct an expression vector containing the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence using only the VEGF-2 coding sequence contained in the ATCC Deposit No. 75698 and the nucleotide sequence of Figure 1 of the HGS application which contains a nucleotide sequence encoding the 350 amino acid form of VEGF-2, and methods and materials known as of March, 1994. I have done this and the experiments I have conducted are described herein.

The Design and Construction of the Expression Vectors Used in the Experiments Described in Power Declaration I

- 4. The Patent Attorneys representing HGS had previously asked that I perform experiments in order to determine whether the 350 amino acid form of VEGF-2 would be secreted from cells when attached to a heterologous signal sequence. To achieve this aim, I transfected eukaryotic cells with expression vectors encoding either (1) the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence, or (2) the 419 amino acid form of VEGF-2. The transfected cells were grown and allowed to express the gene products encoded by the vectors. At various time points, both the cell lysates and culture medium were assayed for the presence of VEGF-2 protein. The presence of VEGF-2 protein in either the cell lysates or culture medium was determined by Western Blot analysis of the samples. I have reviewed my notebooks documenting the experiments I performed to achieve the aims of the experiments described in Power Declaration I and provide the following details:
- 5. For the experiments in Power Declaration I, I was asked to obtain the VEGF-2 DNA directly from the American Tissue Cuiture Collection (ATCC). I did not obtain any constructs from HGS. The only VEGF-2 clones I obtained were ATCC Deposit No. 97149 and ATCC Deposit No. 75698. The Patent

100

Attorneys representing HGS provided to me Figure 1 of the HGS patent specification which contains a nucleotide sequence of the 350 amino acid form of VEGF-2. The HGS Patent Attorneys also provided to me the nucleotide sequence of the 419 amino acid form of VEGF-2. It was my understanding that a nucleotide sequence encoding the 350 amino acid form of VEGF-2 was contained in ATCC Deposit No. 75698 and the nucleotide sequence encoding the 419 amino acid form of VEGF-2 was contained in ATCC Deposit No. 97149. It was also my understanding that the amino acid sequence of the 350 amino acid form of VEGF-2 corresponds to residues 70 to 419 of the 419 amino acid form of VEGF-2.

- 6. As I was under significant time constraints to complete the experiments, I elected to generate the DNA for the expression constructs using only the clone contained in ATCC Deposit No. 97149. Because I was using ATCC Deposit No. 97149 to generate the DNA. I also consulted the nucleotide sequence information relating to the 419 amino acid form of VEGF-2. I considered this to be a reasonable approach since the coding sequences for both the 419 and 350 amino acid forms of VEGF-2 are contained in ATCC Deposit No. 97149. Thus, I isolated the nucleotide sequences encoding the 419 amino acid form of VEGF-2 as well as the 350 amino acid form of VEGF-2 using ATCC Deposit No. 97149 as the sole source of VEGF-2 coding sequences.
- 7. My understanding of the goals of the experiments described in Power Declaration I was to demonstrate that the 350 amino acid form of VEGF-2 could be successfully expressed and secreted when expressed as taught by the HGS patent specification, *i.e.*, using a heterologous signal sequence. I did not inform the patent attorneys representing HGS at the time of carrying out these experiments nor at the time of signing Power Declaration I that I had isolated the 350 amino acid form of VEGF-2 from the ATCC Deposit No. 97149 clone. It was only when they asked on or about September 24, 2001 for


further clarification of the experiments that I conducted that I informed them of these details.

- 8. I have now been asked to redesign my experimental protocol to specifically use the VEGF-2 coding sequence contained in ATCC Deposit No. 75698 to generate the expression construct containing the 350 amino acid form of VEGF-2. I have been asked that I perform the experiments using the VEGF-2 coding sequence contained in ATCC Deposit No. 75698 to determine whether the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence would result in the expression and secretion of the protein from eukaryotic cells.
- I have provided the Patent Attorneys for HGS with the details of a sequence analysis of the VEGF-2 coding sequence contained in ATCC Deposit No. 75698. The VEGF-2 clone contained in the ATCC Deposit No. 75698 lacks 24 amino acids at the N-terminal end of the 350 amino acid form of VEGF-2, and corresponds to residues 94 to 419 of the 419 amino acid form of VEGF-2, i.e., a 326 amino acid form of VEGF-2. I have also been asked to perform experiments to determine if the 326 amino acid form of VEGF-2 as encoded by a nucleotide sequence contained in ATCC Deposit No. 75698 fused to a heterologous signal sequence would result in the expression and secretion of the protein from eukaryotic cells.
- 10. Even though ATCC Deposit No. 75698 lacks the complete coding sequence for the 350 amino acid form of VEGF-2, a molecular biologist as of March 1994 would be able to recreate the 350 amino acid form of VEGF-2 given the description of the complete sequence in the HGS patent specification (as described below) and that is the course I could have taken at that time and I would have expected other molecular biologists to have been able to do the same. I generated an expression vector containing the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence, using only the

ATCC Deposit No. 75698 and the sequence of Figure 1 in the HGS patent specification, and techniques and materials routinely known and used in the art as of March 1994.


The Expression Vector Containing the 350 Amino Acid Form of VEGF-2 Is Generated Using Only ATCC Deposit No. 75698 and Figure 1 of the HGS Patent Specification

11. The general design of the expression vector containing the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence is as follows:




- 12. Since all that I had at my disposal were ATCC Deposit No. 75698 and Figure 1 of the HGS patent specification, I did the following:
 - 12.1 First, I chose to directly isolate a nucleotide sequence encoding the C-terminal 322 residues of the 326 amino acid form of VEGF-2. The 322 residues corresponding to residues 98 to 419 of the 419 amino acid form of VEGF-2 were amplified by PCR from ATCC Deposit No. 75698. I chose to isolate a VEGF-2 fragment of 322 amino acids to facilitate the cloning of the VEGF-2 coding sequence in frame into the expression constructs. To do so, I designed primers based on the sequence provided in Figure 1 of the HGS patent specification, the sequence of ATCC Deposit No. 75698, and the sequence of restriction enzyme recognition sites, *e.g.*, *MscI* and *NotI*. The resulting 322 amino

acid fragment of VEGF-2 amplified from ATCC Deposit No. 75698 was digested with *Msc* I and *Not* I.




12.2 Using a nucleotide sequence encoding the 350 amino acid form of VEGF-2 contained in Figure 1 of the HGS specification, I designed two double stranded oligonucleotides to encode (once ligated together) a 28 amino acid VEGF-2 fragment. This fragment encompasses the 24 amino acids missing from ATCC Deposit No. 75698 and the additional 4 amino acids missing from the 322 amino acid fragment of the 326 form of VEGF-2. Specifically, once ligated together, the oligonucleotides were designed to result in the generation of a 28 amino acid fragment engineered to have a 5' end with a *BspH I* restriction site overhang and a 3' blunt end compatible with a *Msc I* restriction site as shown below. Methods and materials for generating such double stranded oligonucleotides were routine and known by March, 1994.



12.3 A third double stranded oligonucleotide encoding the secretion signal sequence of the Ig k-chain leader signal sequence that was also used in


the experiments described in Power Declaration I was engineered to contain a *Bam* HI restriction enzyme overhang at the 5' end and a *Bsp* HI restriction enzyme overhang at the 3' end as shown below. Ig k-chain leader signal sequence was a recognized signal sequence available as of March, 1994.



- 12.4 The 322 amino acid VEGF-2 fragment and the three double stranded oligonucleotides described above were ligated and subcloned at once into the *Not I/Bam* HI sites of the expression vector pCMV-I which was described in Power Declaration I. The resulting expression vector contains the construct as described in ¶ 11 above. The VEGF-2 sequence is under the control of a CMV-I promoter, a promoter routinely used as of March, 1994.
- 12.5 The resulting 350 amino acid form of VEGF-2 construct was sequenced and confirmed to be correct and is detailed in Appendix I.
- 13. The design of the expression vector containing the VEGF-2 coding sequence found in ATCC Deposit No. 75698 used in the study results in a construct with the 326 amino acid form of VEGF-2 linked to a heterologous sequence and is as follows:
- 14. To generate the construct, the 322 amino acid VEGF-2 fragment flanked with a *Msc* I site at the 5' end and the *Not* I site at the 3' end was generated as

3.T.

described above (see ¶12.1). I designed two double stranded oliogonucleotides that once ligated together encoded the Ig k-chain leader signal sequence and the four amino acid residues corresponding to residues 94 to 97 of the 419 amino acid form of VEGF-2, i.e., the first four residues of the 326 amino acid form of VEGF-2 of ATCC Deposit No. 75698 engineered to contain a 3' blunt end compatible with a MscI restriction site and a 5' Bam HI site. The 322 amino acid VEGF-2 fragment was simultaneously fused in frame with the two double stranded oliogonucleotides, as shown below, and subcloned into the expression vector pCMV-I Bam HI/ Not I sites. Again, the VEGF-2 sequence is under the control of a CMV-I promoter, a promoter routinely used as of March 1994.



- 15. The sequence of the resulting 326 amino acid form of VEGF-2 construct was confirmed to be correct and is detailed in Appendix II, attached hereto.
- 16. For purposes of the following experiments, I used the expression vector encoding the 419 amino acid form of VEGF-2 described in Power Declaration I (see Power Declaration I ¶¶ 3 to 6).
- 17. As set out in Power Declaration I, the sequence of the construct was confirmed to be correct and is detailed in Appendix III, attached hereto.

477

Using Only the VEGF-2 Clone Contained in ATCC Deposit No. 75698 Fused in Frame with a Heterologous Signal Sequence, Expression and Secretion of VEGF-2 Is Achieved

- 18. The Patent Attorneys for HGS requested that I perform the following experiments in order to determine whether using only the 350 amino acid form or the 326 amino acid form of VEGF-2 contained in ATCC Deposit No. 75698 fused in frame with a heterologous signal sequence would result in the expression and secretion of VEGF-2 from eukaryotic cells.
- 19. The overall experimental design is as follows: eukaryotic cells were transfected with expression vectors encoding the 419 amino acid form of VEGF-2, the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence, or the 326 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence. The transfected cells were cultured for 24 or 48 hours to allow for expression of the gene products encoded by each vector. In order to determine whether the VEGF-2 gene product was being expressed and secreted, the cell lysates and culture medium were collected to assay for the presence of VEGF-2. The presence of VEGF-2 in either the cell lysates or culture medium was determined by Western Blot analysis of the samples using a rabbit polyclonal antibody to VEGF-2 that recognizes all forms and fragments of VEGF-2. The same antibody was used in Power Declaration I to assay the presence of VEGF-2 proteins.
- 20. The three VEGF-2 constructs encoding the 419, 350 and 326 amino acid forms of VEGF-2 each were transiently transfected in duplicate, using the lipofectin method into the Human Embryonic Kidney cell line, HEK-293 tsA-0. The method of transfection and the cell line were both routinely used as of March, 1994. As a control for transfection efficiency, each construct was cotransfected with the vector pCMV-β-gal. The efficiency of transfection was determined by β-gal staining 48 hours after transfection. As a negative control,

のは高いの

the vector pCMV-I without the addition of any VEGF-2 coding sequences was transfected in parallel.

21. The transfection design is as follows:

6 dishes transfected with: pCMV-I-VEGF-419;

6 dishes transfected with: pCMV-I-signal sequence-VEGF-350;

6 dishes transfected with: pCMV-I-signal sequence-VEGF-326;

6 dishes transfected: pCMV-I;

1 dish transfected with: pCMV-I-VEGF-419 + pCMV-β-gal;

1 dish transfected with: pCMV-I-signal sequence-VEGF-350 + pCMV-

β-gal; and

1 dish transfected with: pCMV-I-signal sequence-VEGF-326 + pCMV-

β-gal.

City

- 22. After transfection, DMEM medium containing 3% serum was added to the cells. Aliquots of cell extracts and conditioned medium were prepared from each transfection at: T₀ hours, T₂₄ hours and T₄₈ hours, in duplicate.
- 23. At the time of harvesting the cells and medium were treated as follows:

Medium: Harvested medium was concentrated 3 fold using Centricon 10 concentrator devices. One volume of 2 x PAGE loading dye was added to each sample.

Cell Extracts: The cells were harvested by trypsinization and collected by centrifugation. The cell pellet was resuspended and lysed, and one volume of 2 x PAGE loading dye was added to each sample.

24. To determine the transfection efficiency, dishes transfected with the pCMV-β-gal construct were fixed and stained for β-gal activity 48 hours after transfection. All dishes were found to have the same percentage of transfected cells (70%).

- 25. Each protein sample was subjected to Western analysis as outlined below. Prior to loading on to a 12% (w/v) Tris-Glycine SDS-Polyacrylamide gel, the samples were boiled for 5 minutes and cooled on ice. The two end lanes of each gel contained the appropriately sized molecular weight markers to estimate the migration rate of proteins predicted to run in the 16 to 85 kDa size range. The samples were electrophoresed according to standard conditions.
- Each membrane was blocked by a one hour incubation in phosphate buffered saline (PBS) containing 3% Bovine Serum Albumin (BSA). The blot was then incubated at 4°C in PBS containing 0.1% BSA and 500ng/ml of purified rabbit anti-VEGF-2 antibody, a polyclonal antibody which recognizes all immunogenic fragments of VEGF-2. After three 5 minute washes in PBS containing 0.1% Tween, the blot was incubated for 1 hour in PBS containing 0.1% BSA and a 1:3000 dilution of Goat Anti-Rabbit IgG Horse Radish Peroxidase (HRP) conjugated antibody. The blot was washed six times for 5 minutes in PBS containing 0.1% BSA. The blot was developed with 2ml/blot of ECL detection reagent (obtained from Amersham) for one minute and then exposed directly to Polaroid films for approximately 2-3 seconds.
- 27. The result of the experiment is shown in Figure 1, attached hereto. The samples included in the figure are as follows:

Immunoblot analysis of VEGF constructs transiently expressed in HEK293T cells

Lane	Pellet/ Supernatant	Construct (419, 350, 326, or neg. control)	T (h) post-transfection
Gel 1	Dupermatant	j (113, 550, 550, 61 nog. 5010. 53)	·
1	P	Negative control	24
2	S	Negative control	24
3	P	350-signal	24
4	S	350-signal	24
5	P	326-signal	24

....

6	S	326-signal	24
7	P	419	48
8	S	419	48
Gel 2	?		
1	P	Negative control	24
2	S	Negative control	24
3	P	350-signal	24
4	S	350-signal	24
5	P	326-signal	24
6	S	326-signal	24
7	P	419	48
8	S	419	48
Gel 3	3		
1	P	Negative control	24
2	S	Negative control	24
3	P	419	24
4	S	419	24
5	P	419	24
6	S	419	24
7	P	350-signal	48
8	S	350-signal	48
9	P	419	48
10	S	419	48
Gel 4	1		-
1	P	Negative control	48
2	S	Negative control	48
3	P	350-signal	48
4	S	350-signal	48
5	p	326-signal	48
6	S	326-signal	48
7	P	326-signal	48
8	S	326-signal	48

777 1410

10 mm

9	P	419	48
10	S	419	48

31. The Western Blot analysis indicates a broad band resolving at approximately 30kDa was present in the medium collected from the transfection of the 419 amino acid VEGF-2 construct, the 350 amino acid VEGF-2 signal sequence construct, and the 326 amino acid VEGF-2 signal sequence construct (see Figure 1, attached hereto as Appendix IV). The secreted protein was visible at 24 hours and 48 hours after transfection. The secreted product from cells containing the 419 amino acid VEGF-2 construct, the 350 amino acid VEGF2 signal sequence construct, and the 326 amino acid VEGF-2 signal sequence construct are all the same approximate size.

AND I declare that all the statements made in this Declaration are of my own are true in every particular, and that all statements made on information and belief are believed to be true.

Sworn by the said Susan Power,	Cusan Pomer	a
Phillipsburg, New Jersey, on this 27 day of March	h 2002;	
before me Gean Rotmotrenko	•	
Notary Public		

GEAN ROTMISTRENKO
Notary Public, State of New York
No. 41-4778718
Qualified in Queens County
Cartificate Filed in New York County
Commission Expires October 31, 2025

VEGF-350+Signal

ļ	BamHI N∞I		
Ì	Met Glu Thr Asp Thr Leu Leu Leu Trp	Val Leu Leu Leu	· · · · · · · · · · · · · · · · · · ·
ļ	1 GGATCCGCCA CCATGGAGAC AGACACACTC CTGCTATGG		
	CCTAGGCGGT GGTACCTCTG TCTGTGTGAG GACGATACC	C ATGACGACGA	
i	1 Let Trp Val Pro Gly Ser Thr Gly Asp Met Thr Val Leu Ty		
٩	S1 CTGGGTTCCA GGTTCCACTG GTGACATGAC TGTACTCTA		
	GACCCAAGGT CCAAGGTGAC CACTGTACTG ACATGAGAT Tr. Lys Met Tyr Lys Cys Gin Leu Arg Lys Giv Giv Trp (o de la com unicación que
· ·		3In His Asn Arg	
- 4	GGAAAATGTA CAAGTGTCAG CTAAGGAAAG GAGGCTGGC CCTTTTACAT GTTCACAGTC GATTCCTTTC CTCCGACCG		<i>:</i>
	Giu Gin Ala Asn Leu Asn Ser Ang Thr Giu Giu Thr Ile	Lys Phe Ale Ale	* * * * * * * * * * * * * * * * * * * *
15			
i	CTTGTCCGGT TGGAGTTGAG TTCCTGTCTT CTCTGATAT		•
	Bgill	· · · · · · · · · · · · · · · · · · ·	
-	1 Ala Ala His Tyr Asn Thr Glu lie Leu Lys Ser lie Asp As	n Giu Trp Arg Lys	-X-
20	AGCACATTAT AATACAGAGA TCTTGAAAAG TATTGATAA	GAGTGGAGAA	
	TCGTGTAATA TTATGTCTCT AGAACTTTTC ATAACTATT		
ļ	Sphi		
ļ	Lys Thr Gin Cys Met Pro Arg Glu Val Cys ile Asp Val C		•
25	1		•
	TCTGAGTTAC GTACGGTGCC CTCCACACAT ATCTACACCC	Alaman makamanan and ali ili ili ili ili ili ili ili ili ili	
	Trai	Acci	
30			
30 ₁	GGAGTCGCGA CAAACACCTT CTTTAAACCT CCATGTGTGT CCTCAGCGCT GTTTGTGGAA GAAATTTGGA GGTACACACA		••
+	1 Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gin Cys Me		
- 35			•
	TACACCCCA ACGACGTTAT CACTCCCGA CGTCACGTAC		
•	The Control of the Co	ro Leu Ser Gin	The state of the s
40	CGAGCTACCT CAGCAAGACG TTATTTGAAA TTACAGTGCC	TCTCTCTCAA	•
	GCTCGATGGA GTCGTTCTGC AATAAACTTT AATGTCACGG	AGAGAGAGTT	
*	Gly Pro Lys Pro Val Thr Ile Ser Phe Ala Asn His Thr	Ser Cys Arg Cys	
45	The second of th		
	CCGGGGTTTG GTCATTGTTA GTCAAAACGG TTAGTGTGAA	GGACGGCTAC	
_ 1	+1 Cys Met Ser Lys Lau Asp Val Tyr Arg Gin Val His Ser Ila		
50	The state of the s	ATTAGACGTT	
	GTACAGATTT GACCTACAAA TGTCTGTTCA AGTAAGGTAA +1 Ser Leu Pro Ala Thr Leu Pro Gin Cvs Gin Ala Ala Asan L		·
55			
55.	CCCTGCCAGC AACACTACCA CAGTGTCAGG CAGCGAACAA GGGACGGTCG TTGTGATGGT GTCACAGTCC GTCGCTTGTT	GACCTGCCCC	
+	Thr Asn Tyr Met Trp Asn Asn His lie Cys Arg Cys Leu		
601			
	TGGTTAATGT ACACCTTATT AGTGTAGACG TCTACGGACC		•
•	Asp Phe Met Phe Ser Ser Asp Ala Gly Asp Asp Ser Thr Asp		
651	TTTTATGTTT TCCTCGGATG CTGGAGATGA CTCAACAGAT	GGATTCCATG	
	AAAATACAAA AGGAGCCTAC GACCTCTACT GAGTTGTCTA	CCTAAGGTAC	•
			· · · · · · · · · · · · · · · · · · ·

VEGF-350+Signal ·

	i		
	+1	Asp lie Cys Gly Pro Asn Lys Glu Leu Asp Glu Glu Thr Cys Gin Cys Vai	•
· 70	21	ACATCTGTGG ACCAAACAAG GAGCTGGATG AAGAGACCTG TCAGTGTGTC	
	j	TGTAGACACC TGGTTTGTTC CTCGACCTAC TTCTCTGGAC AGTCACACAG	
]	Bsr81	
	1	Cys Arg Ala Gly Leu Arg Pro Ala Ser Cys Gly Pro His Lys Glu Leu Asp	
75	1	TGCAGAGCGG GGCTTCGGCC TGCCAGCTGT GGACCCCACA AAGAACTAGA	
	1	ACGTCTCGCC CCGAAGCCGG ACGGTCGACA CCTGGGGTGT TTCTTGATCT	
	+1	Asp Arg Asn Ser Cys Gin Cys Vai Cys Lys Asn Lys Lau Phe Pro Ser Gin Cys	
80	1	CAGAAACTCA TGCCAGTGTG TCTGTAAAAA CAAACTCTTC CCCAGCCAAT	
		GTCTTTGAGT ACGGTCACAC AGACATTTTT GTTTGAGAAG GGGTCGGTTA	
	+1	Cyr. Gly Ala Asn Arg Glu Phe Asp Glu Asn Thr Cys Gin Cys Val Cys Lys	
8 5	1.	GTGGGGCCAA CCGAGAATTT GATGAAAACA CATGCCAGTG TGTATGTAAA	
	1	CACCCCGGTT GGCTCTTAAA CTACTTTTGT GTACGGTCAC ACATACATTT	
	1	Arg Thr Cys Pro Arg Asn Gin Pro Leu Asn Pro Gly Lys Cys Ala Cys Glu	·
90	1 1	AGAACCTGCC CCAGAAATCA ACCCCTAAAT CCTGGAAAAT GTGCCTGTGA	
		TCTTGGACGG GGTCTTTAGT TGGGGATTTA GGACCTTTTA CACGGACACT	
	+1	Glt Cys Thr Glu Ser Pro Gln Lys Cys Leu Leu Lys Gly Lys Lys Phe His His	
9.5	\$1	ATGTACAGAA AGTCCACAGA AATGCTTGTT AAAAGGAAAG AAGTTCCACC	
	1_	TACATGTCTT TCAGGTGTCT TTACGAACAA TTTTCCTTTC TTCAAGGTGG	
	1	His Gin Thr Cys Ser Cys Tyr Arg Arg Pro Cys Thr Asn Arg Gin Lys Ala	
100	વૃંદ	ACCAAACATG CAGCTGTTAC AGACGGCCAT GTACGAACCG CCAGAAGGCT	•
	1_	TGGTTTGTAC GTCGACAATG TCTGCCGGTA CATGCTTGGC GGTCTTCCGA	
	†1	Cys Glu Pro Giy Phe Ser Tyr Ser Glu Glu Val Cys Arg Cys Val Pro Ser	
105	5 1	TGTGAGCCAG GATTTTCATA TAGTGAAGAA GTGTGTCGTT GCGTCCCTTC	
		ACACTCGGTC CTAAAAGTAT ATCACTTCTT CACACAGCAA CGCAGGGAAG	
	1	Noti	•
	1.	Eagl	
	+1	Sei Tyr Trp Lys Arg Pro Gin Met Ser	
110	าไร	ATATTGGAAA AGACCACAAA TGAGCTAAGC GGCCGCG	

101 ATATTGGAAA AGACCACAAA TGAGCTAAGC GGCCGCG
TATAACCTTT TCTGGTGTTT ACTCGATTCG CCGGCGC

医验验

VEGF 326+Signal

	BamHi Ncoi	
	Met Glu Thr Asp Thr Leu Leu Tro Val Leu Leu Leu Leu	
	THE COLUMN CON THE CONTROL OF THE COLUMN COLUMN CONTROL OF THE COLUMN CONTROL OF THE COLUMN COLUM	
	1 GGATCCGCCA CCATGGAGAC AGACACACTC CTGCTATGGG TACTGCTGCT	
	CCTAGGCGGT GGTACCTCTG TCTGTGTGAG GACGATACCC ATGACGACGA	
	+1 Let Trp Val Pro Gly Ser Thr Gly Asp Arg Glu Gln Ala Ash Leu Ash Ser Arg	
	51 CTGGGTTCCA GGTTCCACTG GTGACAGAGA ACAGGCCAAC CTCAACTCAA	
	GACCCAAGGT CCAAGGTGAC CACTGTCTCT TGTCCGGTTG GAGTTGAGTT	
	Egill	
	1 Ang Thr Glu Glu Thr lie Lys Phe Ala Ala Ala His Tyr Asn Thr Glu lie	
1 (LQ1 GGACAGAAGA GACTATAAAA TTTGCTGCAG CACATTATAA TACAGAGATC	
•		•
	CCTGTCTTCT CTGATATTTT AAACGACGTC GTGTAATATT ATGTCTCTAG	
	Egill Sphi	
	+1 Leu Lys Ser lie Asp Asn Giu Trp Arg Lys Thr Gin Cys Met Pro Arg Giu	
15	L51 TTGAAAAGTA TTGATAATGA GTGGAGAAAG ACTCAATGCA TGCCACGGGA	
	AACTITICAT AACTATTACT CACCICITIC TGAGTTACGT ACGGTGCCCT	-
• •••	Dra	
	+1 -Git Val Cys lie Asp Val Gly Lys Glu Phe Gly Val Ala Thr Asn Thr Phe Phe-	•
	The state of the s	
20	201 GGTGTGTATA GATGTGGGGA AGGAGTTTGG AGTCGCGACA AACACCTTCT	
	CCACACATAT CTACACCCCT TCCTCAAACC TCAGCGCTGT TTGTGGAAGA	
	Drai Acci	
	+1 Phe Lys Pro Pro Cys Val Ser Val Tyr Arg Cys Gly Gly Cys Cys Asn Ser	
2.9	TTAAACCTCC ATGTGTGTCC GTCTACAGAT GTGGGGGTTG CTGCAATAGT	
	AATTTGGAGG TACACACAGG CAGATGTCTA CACCCCCAAC GACGTTATCA	
	Che Che Law Che Che Che The Ch	
3 ()	Ol GAGGGGCTGC AGTGCATGAA CACCAGCACG AGCTACCTCA GCAAGACGTT	
	CTCCCCGACG TCACGTACTT GTGGTCGTGC TCGATGGAGT CGTTCTGCAA	
	+1 Let Phe Glu lie Thr Val Pro Leu Ser Gin Gly Pro Lys Pro Val Thr Ile Ser	
3.5	51 ATTTGAAATT ACAGTGCCTC TCTCTCAAGG CCCCAAACCA GTAACAATCA	
	TAAACTTTAA TGTCACGGAG AGAGAGTTCC GGGGTTTGGT CATTGTTAGT	
3	1 Ser Phe Ala Asn His Thr Ser Cys Ang Cys Met Ser Lys Leu Asp Val Tyr	
4.0	01 GTTTTGCCAA TCACACTTCC TGCCGATGCA TGTCTAAACT GGATGTTTAC	
. , -	CAAAACGGTT AGTGTGAAGG ACGGCTACGT ACAGATTTGA CCTACAAATG	
	And Clark 14.	
	Arg Gin Val His Ser Ile Ile Arg Arg Ser Leu Pro Ala Thr Leu Pro Gin	
45	5] AGACAAGTIC ATTCCATTAT TAGACGTICC CTGCCAGCAA CACTACCACA	
	TCTGTTCAAG TAAGGTAATA ATCTGCAAGG GACGGTCGTT GTGATGGTGT	
	-1 Gir Cys Gin Ala Ala Asn Lys Thr Cys Pro Thr Asn Tyr Met Trp Asn Asn His	
50	01 GTGTCAGGCA GCGAACAAGA CCTGCCCCAC CAATTACATG TGGAATAATC	
., •	CACAGTCCGT CGCTTGTTCT GGACGGGGTG GTTAATGTAC ACCTTATTAG	
		· · · · · · · · · · · · · · · · · · ·
	The state of the s	
22	51 ACATCTGCAG ATGCCTGGCT CAGGAAGATT TTATGTTTTC CTCGGATGCT	٠.
	TGTAGACGTC TACGGACCGA GTCCTTCTAA AATACAAAAG GAGCCTACGA	·
-	+1 Gly Asp Asp Ser Thr Asp Gly Phe His Asp He Cys Gly Pro Ash Lys Glu	
60	01 GGAGATGACT CAACAGATGG ATTCCATGAC ATCTGTGGAC CAAACAAGGA	
	CCTCTACTGA GTTGTCTACC TAAGGTACTG TAGACACCTG GTTTGTTCCT	
·	BsrBI	** *******
•	-1 Git Leu Asp Giu Giu Thr Cys Gin Cys Val Cys Arg Ala Giy Leu Arg Pro Ala	
03		
	CGACCTACTT CTCTGGACAG TCACACAGAC GTCTCGCCCC GAAGCCGGAC	

VEGF 326+Signal

+1	Ala Ser Cys Giy Pro His Lys Giu Leu Asp Arg Asn Ser Cys Gin Cys Val	
7ģ1	CCAGCTGTGG ACCCCACAAA GAACTAGACA GAAACTCATG CCAGTGTGTC	
į	GGTCGACACC TGGGGTGTTT CTTGATCTGT CTTTGAGTAC GGTCACACAG	
7-1	Cys Lys Asn Lys Leu Phe Pro Ser Gln Cys Gly Ala Asn Arg Glu Phe Asp	
7\$1	TGTAAAAACA AACTCTTCCC CAGCCAATGT GGGGCCAACC GAGAATTTGA	
	ACATTTTGT TTGAGAAGGG GTCGGTTACA CCCCGGTTGG CTCTTAAACT	
+ 1	Asp Glu Asn Thr Cys Gln Cys Val Cys Lys Arg Thr Cys Pro Arg Asn Gln Pro	****
801	TGAAAACACA TGCCAGTGTG TATGTAAAAG AACCTGCCCC AGAAATCAAC	
;	ACTITIGIGI ACGGICACAC ATACATITIC ITGGACGGGG TCTTTAGTTG	
	PsrG1	
- 1	Pro Leu Asn Pro Gly Lys Cys Ala Cys Giu Cys Thr Glu Ser Pro Gin Lys	•
851	CCCTAAATCC TGGAAAATGT GCCTGTGAAT GTACAGAAAG TCCACAGAAA	
	GGGATTTAGG ACCTTTTACA CGGACACTTA CATGTCTTTC AGGTGTCTTT	
÷1	Cys Leu Leu Lys Gly Lys Lys Phe His His Gln Thr Cys Ser Cys Tyr Arg	
901	TGCTTGTTAA AAGGAAAGAA GTTCCACCAC CAAACATGCA GCTGTTACAG	
•	ACGAACAATT TTCCTTTCTT CAAGGTGGTG GTTTGTACGT CGACAATGTC	
+1	Arg Arg Pro Cys Thr Asn Arg Gln Lys Ala Cys Glu Pro Gly Phe Ser Tyr Ser	
951	ACGGCCATGT ACGAACCGCC AGAAGGCTTG TGAGCCAGGA TTTTCATATA	
<u> </u>	TGCCGGTACA TGCTTGGCGG TCTTCCGAAC ACTCGGTCCT AAAAGTATAT	
+1	Ser Glu Glu Val Cys Arg Cys Val Pro Ser Tyr Trp Lys Arg Pro Gln Met	
100 1	GTGAAGAAGT GTGTCGTTGT GTCCCTTCAT ATTGGAAAAG ACCACAAATG	
:	CACTTCTTCA CACAGCAACA CAGGGAAGTA TAACCTTTTC TGGTGTTTAC	
:	Noti	
•	Eagl	
+ 1	Ser ***	-
1051	AGCTAAGCGG CCGCG	
	TCGATTCGCC GGCGC	
	The second secon	• • • • • • • • • • • • • • • • • • • •

i		E∽RI	
j	+1	Met His Leu Gly Pho Phe Ser Val Ala	:
i i	1	GAATTCGTGG GTCCTTCCAC CATGCACTTG CTGGGCTTCT TCTCTGTGGC	
,		CTTAAGCACC CAGGAAGGTG GTACGTGAAC GACCCGAAGA AGAGACACCG	
	_	Smal	
		Xmal	
·		Aval Nari	•
	1	Ala Cys Ser Leu Leu Ala Ala Ala Leu Leu Pro Gly Pro Arg Glu Ala Pro Ala GTGTTCTCTG CTCGCCGCTG CGCTGCTCCC GGGTCCTCGC GAGGCGCCCG	·• ·:
1	_	CACAAGAGAC GAGCGCGAC GCGACGAGGG CCCAGGAGCG CTCCGCGGGC	•
	+1	Ala Ala Ala Ala Phe Glu Ser Gly Leu Asp Leu Ser Asp Ala Glu Pro	Market and the second s
10	1	CCGCCGCCGC CGCCTTCGAG TCCGGACTCG ACCTCTCGGA CGCGGAGCCC	
	_	GGCGGCGGC GCGGAAGCTC AGGCCTGAGC TGGAGAGCCT GCGCCTCGGG	
	+1	Asp Ala Gly Glu Ala Thr Ala Tyr Ala Ser Lys Asp Leu Glu Glu Gln Leu	
15	L	GACGCGGGCG AGGCCACGGC TTATGCAAGC AAAGATCTGG AGGAGCAGTT CTGCGCCGC TCCGGTGCCG AATACGTTCG TTTCTAGACC TCCTCGTCAA	
		BspHI	
	- 1	Let Arg Ser Val Ser Ser Val Asp Glu Leu Met Thr Val Leu Tyr Pro Glu Tyr	
20	1	ACGGTCTGTG TCCAGTGTAG ATGAACTCAT GACTGTACTC TACCCAGAAT	
	-	TGCCAGACAC AGGTCACATC TACTTGAGTA CTGACATGAG A'GGGTCTTA	
_	1	Tyr Trp Lys Met Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln His Asn	
25	Ţ	ATTGGAAAAT GTACAAGTGT CAGCTAAGGA AAGGAGGCTG GCAACATAAC TAACCTTTTA CATGTTCACA GTCGATTCCT TTCCTCCGAC CGTTGTATTG	
	1	Arg Glu Gin Ala Asri Leu Asn Ser Arg Thr Glu Glu Thr lie Lys Phe Ala-	
30	lı İ	AGAGAACAGG CCAACCTCAA CTCAAGGACA GAAGAGACTA TAAAATTTGC	
·		TCTCTTGTCC GGTTGGAGTT GAGTTCCTGT CTTCTCTGAT ATTTTAAACG	:
•	1	Ala Ala Ala His Tyr Asn Thr Glu lie Leu Lys Ser lie Asp Asn Glu Trp Arg	
3.5	1	TGCAGCACAT TATAATACAG AGATCTTGAA AAGTATTGAT AATGAGTGGA	
	<u>.</u> 	ACGTCGTGTA ATATTATGTC TCTAGAACTT TTCATAACTA TTACTCACCT Sphi	
,	1	Arg Lys Thr Gin Cys Met Pro Arg Giu Vai Cys ile Asp Vai Giy Lys Giu	
40	1	GARAGACTCA ATGCATGCCA CGGGAGGTGT GTATAGATGT GGGGAAGGAG	
•	ļ	CTTTCTGAGT TACGTACGGT GCCCTCCACA CATATCTACA CCCCTTCCTC	· · · · · · · · · · · · · · · · · · ·
•		Dral Acci	
	• 1 -		
4 5	Ĭ	TTTGGAGTCG CGACAAACAC CTTCTTTAAA CCTCCATGTG TGTCCGTCTA AAACCTCAGC GCTGTTTGTG GAAGAAATTT GGAGGTACAC ACAGGCAGAT	
	ļ-	Acci	
	1	Tyi Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr Ser	
50	<u>)</u>	CAGATGTGGG GGTTGCTGCA ATAGTGAGGG GCTGCAGTGC ATGAACACCA	, ·
	ļ	GTCTACACCC CCAACGACGT TATCACTCCC CGACGTCACG TACTTGTGGT	
55		Ser Thr Ser Tyr Leu Ser Lys Thr Leu Phe Glu lie Thr Val Pro Leu Ser	
	Ĺ	GCACGAGCTA CCTCAGCAAG ACGTTATTTG AAATTACAGT GCCTCTCTCT CGTGCTCGAT GGAGTCGTTC TGCAATAAAC TTTAATGTCA CGGAGAGAGA	
	1	Gln Gly Pro Lys Pro Val Thr. Ile Ser Phe Ala Asn His Thr Ser Cys Arg	
60	1	CAAGGCCCCA AACCAGTAAC AATCAGTTTT GCCAATCACA CTTCCTGCCG	
	ļ †	GTTCCGGGGT TTGGTCATTG TTAGTCAAAA CGGTTAGTGT GAAGGACGGC	regional to the same and accommon

419-VEGF-2

	the Arm Cive Met Ser I we low App. Vol. Time App. Cla. Vol. U. C	٠.
`• :	11 Arg Cys Met Ser Lys Leu Asp Val Tyr Arg Gin Val His Ser lie lie Arg Arg	
. 63	1 ATGCATGTCT AAACTGGATG TTTACAGACA AGTTCATTCC ATTATTAGAC	•
	TACGTACAGA TTTGACCTAC AAATGTCTGT TCAAGTAAGG TAATAATCTG	
	-1 Arg Ser Leu Pro Ala Thr Leu Pro Gin Cys Gin Ala Ala Asn Lys Thr Cys	
.70	The state of the s	
	CAAGGGACGG TCGTTGTGAT GGTGTCACAG TCCGTCGCTT GTTCTGGACG	
	1 Pro Thr Asn Tyr Met Trp Asn Asn His He Cys Arg Cys Leu Ale Gin Glu	
75	1 CCCACCAATT ACATGTGGAA TAATCACATC TGCAGATGCC TGGCTCAGGA	
	GGGTGGTTAA TGTACACCTT ATTAGTGTAG ACGTCTACGG ACCGAGTCCT	<i>:</i>
	1 Gli Asp Phe Met Phe Ser Ser Asp Ala Gly Asp Asp Ser Thr Asp Gly Phe His	-
6 d		
(*	TCTAAAATAC AAAAGGAGCC TACGACCTCT ACTGAGTTGT CTACCTAAGG	
	1 His Asp lie Cys Gly Pro Asn Lys Glu Leu Asp Glu Glu Thr Cys Gin Cys	
25		
6.7	THE PROPERTY OF THE PROPERTY OF THE PROPERTY CANADAGE CANADAGE	
	TACTGTAGAC ACCTGGTTTG TTCCTCGACC TACTTCTCTG GACAGTCACA BirBi	

}	Cys Gid Leu	
90		
	CAGACGTCTC GCCCCGAAGC CGGACGGTCG ACACCTGGGG TGTTTCTTGA	
i	1 Let Asp Arg Ash Ser Cys Gin Cys Val Cys Lys Ash Lye Leu Phe Pro Ser Gin	: · · · · · · · · · · · · · · · · · · ·
95	The second didinates that of the compact	
	TCTGTCTTTG AGTACGGTCA CACAGACATT TTTGTTTGAG AAGGGGTCGG	
1	1 Gir Cys Gly Ala Asn Arg Glu Phe Asp Glu Asn Thr Cys Gin Cys Val Cys	
100	AATGTGGGGC CAACCGAGAA TTTGATGAAA ACACATGCCA GTGTGTATGT	
	TTACACCCCG GTTGGCTCTT AAACTACTTT TGTGTACGGT CACACATACA	
	1 Lys Arg Thr Cys Pro Arg Asn Gln Pro Leu Asn Pro Gly Lys Cys Ala Cys	
105	AAAAGAACCT GCCCCAGAAA TCAACCCCTA AATCCTGGAA AATGTGCCTG	•
	TTTTCTTGGA CGGGGTCTTT AGTTGGGGAT TTAGGACCTT TTACACGGAC	:
	1 Cys Glu Cys Thr Glu Ser Pro Gln Lys Cys Leu Leu Lys Gly Lys Lys Phe His-	
110		
	ACTTACATGT CTTTCAGGTG TCTTTACGAA CAATTTTCCT TTCTTCAAGG	
+	1 His His Gin Thr Cys Ser Cys Tyr Arg Arg Pro Cys Thr Asn Arg Gin Lys	
115		
	TGGTGGTTTG TACGTCGACA ATGTCTGCCG GTACATGCTT GGCGGTCTTC	• • •
····		
120		•
120		
	CGAACACTCG GTCCTAAAAG TATATCACTT CTTCACACAG CAACACAGGG	
	Not!	
) !-	Eagl	
	Pro Ser Tyr Trp Lys Arg Pro Gin Met Ser	
125		
	AAGTATAACC TTTTCTGGTG TTTACTCGAT TCGCCGGCGC	; ;

100 mm